|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safe-ty of a 4-factor prothrombin complex concentrate in patientson vitamin K antagonists presenting with major bleeding: arandomized, plasma-controlled,phase HI b study显示文摘 | Sarode R Milling TJ Jr Refaai MA | 2013 | Circula-tion2013，128，11： | 1 |
| 2 | Interdigitating dendritic cell sarcoma of the parotid gland: case report and literature review显示文摘 | Efune G Sumer B D Sarode V R | 2009 | Am J Otolaryngol2009，30，4： | 1 |
| 3 | Massive blood transfusion显示文摘 | Downes K Sarode R | 2001 | Indian J Pediatr2001，68，2： | 1 |
| 4 | Whole blood in the management of hypovolemia due to obstetric hemorrhage 显示文摘 | Alexander JM Sarode R Mcintire DD | 2009 | Obstet Gynecol2009，113，6： | 1 |
| 5 | A massive transfusion protocol to decrease blood component use andcosts显示文摘 | O'Keeffe T Refaai M Tchorz K Forestner JE Sarode R | 2008 | ArchSurg2008，143，7： | 1 |
| 6 | Thrombotic thrombocyto- penic purpura :2012 American Society for Apheresis (ASFA) Consen- sus Conference on Classification, Diagnosis, Management, and Future Research显示文摘 | Sarode R Bandarenko N Brecher ME | 2014 | J Clin Apher2014，29，3： | 1 |
| 7 | Exploring antagonistic metabo-lites of established biocontrol agent of marine origin 显示文摘 | RANE M R SARODE P D | 2008 | AppliedBiochemistry Biotechnology2008，151，3： | 1 |
| 8 | Massive blood transfusion显示文摘 | Downes K Sarode R | 2001 | Indian J Pediatr2001，68，2： | 1 |
| 9 | Approach to the assessment of platelet function:comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods显示文摘 | Dyszkiewicz-Korpanty AM Frenkel EP Sarode R | | 0，，01： | 1 |
| 10 | Crossing of infraingui- nal peripheral arterial chronic total occlusion with a blunt micro dissection catheter 显示文摘 | Banerjee S Thomas R Sarode K | 2014 | J Invasive Cardiol2014，26，8： | 1 |
| 11 | Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura显示文摘 | Tsai HM Rice L Sarode R | | 0，，10： | 1 |
| 12 | 显示文摘 | Tssai HM Rice L Sarode R | 2000 | Ann Int Med2000，132，4： | 1 |
| 13 | Novel thrombin and factor Xa inhibitors:challenges to reversal of their anticoagulation effects显示文摘 | Yates S Sarode R | 2013 | Curr Opin Hematol2013，20，： | 1 |
| 14 | Formation of Ce1-xPdxO2-delta solid solution in combustion-synthesized Pd/CeO2 catalyst:xrd,xps,and exafs investigation显示文摘 | Priolkar K R Bera P Sarode P R | 2002 | Chem Mat2002，14，5： | 1 |
| 15 | Quality of life and oral potentially malignant disorders: Critical appraisal and prospects显示文摘Quality of life(QoL) is a vital and often required health outcome measure that is relevant to patient care. A healthy oral cavity enables person to perform daily activities without any limitations. However, any disturbance may result in impaired QoL. The oral health-remains an essential element of people's health and well-being. In recent years, the tradition of clinical practice and research has been changed by incorporating QoL assessment, as it helps in assessment of patients' needs and monitoring treatment responses. Oral potentially malignant disorders(OPMDs) are a group of chronic disorders including oral leukoplakia(OL), oral lichen planus and oral submucous fibrosis(OSF). It is evident that patients with OPMDs experience significant health-related symptoms, functional limitations and psycho-social impairment, compromising their Qo L. Moreover, the worsening of Qo L has been associated with advanced stages of OPMDs. Despite of increasing number of OPMD cases in recent decades, limited literature is available regarding QoL in this population. Although, there is higher prevalence of habit-related OPMDs, particularly OSF and OL in Southern Asian countries, only a few studies have been performed in these populations. Moreover, these studies administered generic Qo L instruments, which offer less sensitivity to clinical changes. However, condition-specific instruments are more sensitive and allows better measurement of QoL. As the impacts of different conditions on OHRQoL may vary, the development and validation of a QoL instrument specific to each clinical entity of OPMDs is currently needed. | Shailesh M Gondivkar Rahul R Bhowate Amol R Gadbail Sachin C Sarode Shankargouda Patil | 2018 | World Journal of Clinical Oncology2018，9，4： | 1 |
| 16 | Novel thrombin and factor Xa inhibitors:challenges to reversal of their anticoagulation effects 显示文摘 | YATES S SARODE R | 2013 | CurrOpin Hematol2013，20，6： | 1 |
| 17 | Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura显示文摘 | Patino W Sarode R | 2007 | J Clin Apher2007，22，1： | 1 |
| 18 | Whole blood in the management of hypovolemia due to obstetric hemorrhage 显示文摘 | Alexander J M Sarode R McIntire D D | 2009 | Obstet Gynecol2009，113，6： | 1 |
| 19 | Thrombotic thrombocytope- nic purpura: early and late responders 显示文摘 | Sarode R Gottschall JL Aster RH | 1997 | Am J Hematol1997，54，2： | 1 |
| 20 | Thrombotic thrombocytopenic purpura:Early and late responders显示文摘 | Sarode R Gottschalla J L Aster R H | 1997 | Am J Hematol1997，54，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员